HOME >> BIOLOGY >> NEWS
New study finds link between decline in the city's TB rates and intensified control programs

d with TB bacteria and that around 10 percent of infected individuals will develop active TB at some time in their lives.

TB is different from many other bacterial infections in that disease can be caused by either reactivation of latent infection acquired years earlier or as a result of recently acquired infection followed by rapid progression to active disease. TB cases due to recently acquired infection--or clustered cases--indicate the amount of transmission that is occurring within the population, while non-clustered cases provide an index of TB resulting from reactivation of latent infection, in which a person was infected many years earlier.

Previous studies have shown that DNA fingerprinting of the TB bacteria allows tracking of specific strains. With this information the research team was able to determine patterns of how different strains moved among population groups causing TB.

"In San Francisco we had detected a sizable amount of transmission of TB in the early 90s, so TB control measures were established that focused on halting the spread of TB and especially reducing the number of clustered cases. The intensified TB control measures focused on preventing transmission and on the use of effective preventive therapy," Jasmer said.

Measures included improved communication between TB control investigators and populations at risk, such as the homeless and substance abusers; expanded use of directly observed therapy, in which health care workers supervise the care of TB patients; development of an HIV-related TB prevention program; improved screening among persons in residential care facilities, jails, and homeless shelters; and improved hospital infection control measures.

"Although we have made considerable progress in decreasing the rate of cases and especially those cases due to recently acquired infection, there is still a large pool of persons infected from the extensive transmission of the previous 15 years. We are focusin
'"/>

Contact: Corinna Kaarlela
ckaarlela@pubaff.ucsf.edu
415-476-3804
University of California - San Francisco
15-Jun-1999


Page: 1 2 3

Related biology news :

1. Student science contest participation influences study, career choices, alumni say
2. New study shows hope for treating inhalant abuse
3. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
4. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
5. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
6. Phase II trials of second-generation antisense cancer drug planned following successful early study
7. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
8. Indiana University, EPA to study airborne PCBs
9. K-State, other universities to study how climate affects plant evolution
10. USC study links historical increases in life span to lower childhood exposure to infection
11. Washington University in St. Louis leads group studying aging process

Post Your Comments:
(Date:10/22/2014)... -- Leading identity analyst firm Acuity Market Intelligence forecasts that ... will have a chip-based National eID card, including near-complete ... Asia , with its vast population, is ... 60% of all National eID cards issued between 2014 ... National eID Industry Report: 2014 Edition" — ...
(Date:10/18/2014)... Berlin, 19th October 2014 Psychological stress and stress-related ... for aging-related diseases, but the molecular mechanisms ... mechanisms may contribute to the development of ... treatments for these devastating diseases. This work ... Neuropsychopharmacology congress in Berlin., Now an international ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
(Date:10/25/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... the development of oral drug delivery systems, announced today ... present at FireRock Capital,s Micro-Cap Conference. ... Tuesday, October 28, 2014 ,Time: 9:15am EST ,Location: The ... , About The FireRock Conference  ...
(Date:10/25/2014)... , Oct 24, 2014 Research ... "Epigenetics Market by Product , Research Area & ... report to their offering. In this ... basis of products, research areas, and end users. The ... report are enzymes, instruments & consumables, kits, and reagents. ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
Breaking Biology Technology:Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2
Cached News: